Dattatreya also said the ministry is working on consolidating 44 labour codes into four in order to simplify them. Labour Minister Bandaru Dattatreya. New Delhi: The retirement fund body EPFO&auto parts bearingss Manufacturers39;s investment in stocks through exchange traded funds (ETFs) would cross the Rs. 45,000-crore mark by the end of this fiscal, Labour Minister Bandaru Dattatreya said on Thursday."In the exchange traded funds, we have increased (investment) from 10 per cent to 15 per cent. With this, this year alone, it may go in totality to Rs. 45,000 crore, and I feel (that) the rate of return last year was 13.3 per cent (from ETFs)," Dattatreya said on the sidelines of an Assocham event here.

The markets are good and let's see the situation, but it is an encouraging one. That's why we have increased (investment)," he said.As of April 21 this year, the stock investment stood at Rs. 21,559 crore. The EPFO invested Rs.6,577 crore in 2015-16 and Rs. 14,982 crore in 2016-17.Dattatreya also said the ministry is working on consolidating 44 labour codes into four in order to simplify them.The four codes pertain to labour, industrial relations, social security and welfare and safety and working conditions.Besides, he said the government plans to create 65 million jobs by 2026 in the auto sector alone.Speaking on the occasion, Secretary, Heavy Industries and Public Enterprises, Girish Shankar said there is a huge gap the auto industry must address to ensure Make in India delivers. Original equipment manufacturers (OEMs) need to make substantial investment in engineering R&D for designing and developing in India so that India graduates to a truly auto engineering hub."We request the auto majors to consider this seriously and fast enough. Also, suggest to us as to how to support this through an appropriate policy framework. We are already working towards this direction," he said.The ministry has finalised the net automotive mission plan (AMP) 2016-26, he said, adding that AMP 2026 is a combined effort of the central government and the industry.It also seeks to define the trajectory of evolution of the automotive ecosystem in India including the glide path of specific regulations and policies that govern a wide range of parameters affecting the industry."As an outcome of the AMP 2026, we are planning that the Indian automotive industry will grow 3.5-4 times in value from its current output of around Rs. 4,64,000 crore in 2015 to about Rs. 16,16,000-18,89,500 crore by 2026, considering an average GDP growth ranging between 5.8 per cent and 7.5 per # cent during the period," he said.

The high cost of upgrading existing diesel engines to the BS 6 norms has prompted the automakers to take the hard decision. Though most manufacturers have begun the process of aligning their capacities and ca pabilities to the emerging scenario, certain component suppliers for turbochargers and fuel injection component would be hard hit, according to industry captains and auto analysts.“As India moves towards reducing carbon emissions significantly in the years to come, we believe there will be further opportunities beyond diesel/gasoline vehicles and others,” he said, adding that he expects the compact car segment to accelerate towards petrol engines, to begin with.At present diesel cars at Maruti, which sells one car out of two bought in the country, account for almost a third of its sales. Its spokesman said the demand for hybrid and electrical architectures will increase in order to comply with the new emissions regulations.Doreswamy also expects opportunities to develop in the hybrid vehicles.Three weeks ago, Maruti Suzuki, the biggest diesel car maker, announced it would stop making diesel vehicles from April 1, 2020 when the new BS 6 fuel emission norms will be introduced.

Most automotive manufacturers in India are well-prepared to meet the BS 6 emission regulations from 2020 as they have been exporters of vehicles/ automotive components to countries where Euro 6 standards exist,” Prashanth Doreswamy, Market Head at Continental India and MD at Continental Auto-motive India, said.Ray said component manufacturers are already aware of underlying changes in the industry and they are aligning their capacity accordingly.Vinnie Mehta, Director General of the Automotive Component Manufactur-ers Association of India, or ACMA, said while the component makers have had a great run with the diesel category, there is another opportunity of catering to huge vehicle parc (a European term for total number of vehicles in use) in the country which needs repairing and maintenance. Mahindra, the third biggest passenger vehicle maker, and Tata Motors also joined in.Some companies like Schaeffler India have mentioned the impact of this in their recent quarterly calls, she pointed out.However, diversified companies across products and segments, such as passenger vehicles, commercial vehicles, two-wheelers and tractors, would be more insulated from such shocks, Ponniah explained. Pune: The auto component industry is bracing for the tectonic shift in the automobile sector from the expected exit of diesel cars and arrival of electric vehicles..BorgWarner, US based company, said it was constantly developing technologies to help companies, as the automotive industry is characterised by constant changes.

Casting & forging suppliers will not be significantly impacted, as loss of diesel business can be compensated by gain in petrol – assuming they are supplier for both engine platforms,” he said. Moreover, disel cars meeting BS 6 fuel emission norms would be costlier by Rs 2 lakh to Rs 3 lakh.On transition to electric vehicles, Ray said it is still sometime away and hence, it is unlikely to have any material impact on component-makers performance over the next five years. “The transition from combustion engine to e-mobility will massively pick up speed between 2025 and 2030,” he said.Specific component firms manufacturing products for turbochargers, feul injection, diesel filters and a few engine components (diesel power train typically has more content than petrol engines) would be more impacted than process capabilities companies, Pavethra Ponniah, Vice President and Sector Head, Corporate Sector Ratings at ICRA, said.Some companies like Schaeffler India have mentioned the impact of this in their recent quarterly calls, she pointed out.He said in April 2018, ICRA China auto bearings factorys Suppliers has estimated that diesel share in passenger vehicles will decline below 25 per cent by FY2022.However, certain component suppliers for turbochargers and fuel injection component may witness some impact on their revenue and profitability, Ray pointed out.“After market supplier service is big business and component manufacturers have the existing market to supply spare parts,” he said, admitting that the industry was facing tough challenges even as diesel car costs would increase 15-20 per cent post BS 6 emission norms. At present diesel cars at Maruti, which sells one car out of two bought in the country, account for almost a third of its sales.“Shift of diesel in passenger vehicles has already declined from 58 per cent in FY2013 to 36-37 per cent in FY2019, and the decline will be even steeper post-BS VI transition,” Subrata Ray, Senior Group Vice President at ICRA rating firm told FC

The star kid is dating a basketball wheel bearings Suppliers player Eban Hyams. She said, "There was no pressure or any awkwardness.The duo has been making several appearances together and recently Krishna confirmed her relationship with Eban on Instagram. ♾ #justforyou @ebanhyams @doitall23A post shared by Krishna Jackie Shroff (@kishushroff) on Sep 3, 2019 at 9:50am PDTIn the above pictures, the couple can be seen passionately loving each other. Apart from these pics, Krishna aka Kishu also shared some romantic holiday photos with Eban on social media.The star kid is dating a basketball player Eban Hyams. Earlier in an interview, Krishna shared a memory of her first date with Eban.

Jackie Shroff's dear daughter and Tiger's sister Krishna Shroff is currently enjoying the sweetness of life. Krishna Shroff with boyfriend Eban Hyams. After the gym, over the weekend, I asked him if he wanted to come out and meet some people because he had just returned to Bombay at the beginning of this year. Sharing a couple of cosy picture of Instagram, Jaggu Dada's daughter wrote, "Minding our own business like it’s our own company, this is destiny, we meant to be, something so special like it’s heavenly. The beach seems to be heaven for them. #justforyou @ebanhyams @doitall23" Minding our own business like it’s our own company, this is destiny, we meant to be, something so special, like it’s heavenly.Have a look: Damn.  blessedwiththebest @ebanhyams @doitall23 ♥️A post shared by Krishna Jackie Shroff (@kishushroff) on Sep 26, 2019 at 1:51am PDTIn the above photos, Krishna is looking super hot in a black bikini while Eban is looking charming in shirtless avatar

Provectus estimates the cost of PV-10 from laboratory to approval will be about $100 million, auto parts bearingss Factory a fraction of the more than $1 billion in research and development for a new drug that the industry often cites to defend against criticism that medicine prices are too high."The biggest value will be if it can affect distant disease," said Hwu, who is not involved in PV-10 testing.In 1998, scientists who later founded Provectus were looking for a safe photo reactive agent to use in an investigation of lasers against cancer. The Knoxville, Tennessee, company reported promising results in a small melanoma study.Rose Bengal's potential against cancer was discovered by accident. and suddenly realizing that they may have an oncologic value," said Dr Vernon Sondak, head of cutaneous oncology at the Moffitt Cancer Center in Tampa, Florida. Sondak has been running clinical trials for Provectus. Agarwala, who has been conducting PV-10 trials funded by Provectus, also has run several cancer immunotherapy studies, including on Keytruda.Immune System Response

The company also has begun a melanoma trial of the drug with Merck's Keytruda, a treatment that works by helping the immune system fight cancer, to see if the combination has a more pronounced effect on slowing disease than either alone. The hope is that the drug, known as PV-10, will prevent melanoma from progressing beyond Stage III, in which the disease has spread but not yet to other organs, and allow patients with more advanced cancer to live longer.The lesions were destroyed from the inside with no apparent harm to healthy tissue, researchers said.As it turned out, the Rose Bengal solution appeared to work on its own to dissolve tumors when directed injectly into them, recalled Provectus Chief Technology Officer Eric Wachter, a former scientist from Oak Ridge National Lab who co-founded the company. Reported side effects included injection site pain and blistering.Doctors said they hoped PV-10 combinations would not create the additional toxicity seen with some other combination therapies because of its mild side effect profile. dc-Cover-lf85j3i254a8mep3al3mq5jtn0-20160226165119. But the final decision on price is likely to be made by a bigger drugmaker, as Provectus plans to put itself up for sale once its drug is approved.Dr Patrick Hwu, an immunotherapy expert from MD Anderson Cancer Center, said PV-10 is one of several interesting tumor ablation techniques in the works. New York: Modern cancer drugs supercharge immune systems, target specific gene mutations and pack modified viruses into vaccines.jpeg Rose Bengal, a cheap industrial chemical that turns yarn and food bright red, has been used as a diagnostic staining agent for some time.At the forefront is Provectus Biopharmaceuticals Inc, which is testing a reformulated version of the industrial dye on melanoma, the deadliest form of skin cancer. A year later, 11 percent continued to show no signs of cancer, according to a report published the Annals of Surgical Oncology.

The company must replicate its early results on a bigger scale, and a US Food and Drug Administration decision is not expected before 2019.Rose Bengal, a cheap industrial chemical that turns yarn and food bright red, has been used as a diagnostic staining agent for some time.Rose Bengal, a cheap industrial chemical that turns yarn and food bright red, has been used as a diagnostic staining agent for some time.While some doctors are encouraged by the research, government approval is years off and not guaranteed.Final results from an ongoing 225-patient melanoma trial of the experimental drug compared to chemotherapy are expected in early 2018.Provectus executives say the small development tab - along with relatively low manufacturing costs and easy handling requirements - could make PV-10 a less expensive new treatment. "It made the lasers obsolete..In addition to PV-10 destroying injected skin lesions, researchers noticed shrinkage in untreated lesions and tumors as far away as the lungs, suggesting it may also provoke an immunue system response."We've come to the conclusion that it is immune based," said Dr Sanjiv Agarwala, chief of medical oncology and hematology at St. Rose Bengal fit the bill. Amid the increasing sophistication, one investigational treatment stands out for its simplicity."This is one of the really neat examples of what we call repurposing, taking drugs that been around for years .. Luke's Cancer Center in Bethlehem, Pa..The $95 million company trades at about 49 cents per share, off a high of 98 cents last April, on very small volumes, possibly reflecting investor uncertainty over the drug's prospects. Now, some scientists are looking at its potential to fight various forms of cancer.Medi_."In a study of 80 people with advanced melanoma, half of the patients who had all of their lesions injected appeared cancer free after an average of two months. The salt was first patented in 1882 as a wool dye and has been used for years as a diagnostic stain in tests for jaundice in newborns and to detect eye damage.Pfizer holds a co-patent on PV-10 for use in combination therapies, and Boehringer Ingelheim has secured right of first refusal on use of the drug against liver cancer in China, the companies told Reuters